SNS, unfortunately no news from Delcath regarding the clinical trials so reason no talk of medical side in my view.
Personally agree that under current CEO things are moving at a snails pace. Previous Phase III under Hobbes was much more efficient. Either qualifying cases are decreasing or enrollment rates are down on current Phase III as with number required they should have finished already by my estimates.
Last I heard 6 treatments is still the target rate but read somewhere that several patients had been pulled after just 2 treatments due to events. Will try to find the source and post if interested.
I think Chemosat is still showing significant improvement over alternative best care but can't say for sure as company being very quiet about anything to do with clinical trial.
News 
Market Data 
Discover 
